QIAGEN N.V. common shares to be removed from NYSE listing

QIAGEN N.V. is having its common shares removed from listing and registration on the New York Stock Exchange.

Rhea-AI Filing Summary

QIAGEN N.V. is having its common shares removed from listing and registration on the New York Stock Exchange. The filing states that the Exchange has followed its own rules to strike this class of securities, and that the company has followed Exchange procedures and regulatory requirements for a voluntary withdrawal from listing and registration. This means QIAGEN’s common shares will no longer trade on the NYSE once the delisting process is effective, and trading would need to occur on other markets or venues if available.

Positive

• None.

Negative

• QIAGEN N.V. common shares will be removed from listing and registration on the New York Stock Exchange, reducing access to this major U.S. trading venue.

Insights

Equity markets and listing standards analyst

QIAGEN’s common shares are being voluntarily delisted from the NYSE.

The filing confirms that QIAGEN N.V. common shares will be removed from listing and registration on the New York Stock Exchange. The Exchange states it has complied with its own rules to strike the securities, while QIAGEN has complied with Exchange rules and regulatory requirements for voluntary withdrawal under the cited SEC provisions.

Removal from a major U.S. exchange can affect how easily shares trade and how visible the company is to certain investors who prefer or require exchange-listed securities. The filing does not provide reasons or any alternative listing venue, so the main takeaway is the confirmed end of this NYSE listing for QIAGEN’s common shares.

The dated signature by an authorized NYSE representative indicates the Exchange’s certification that it meets the conditions to file this notice. Subsequent company or market communications would typically clarify any new primary trading venue or changes in how investors can access the shares.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does this Form 25 filing mean for QIAGEN N.V. (QGEN)?

It states that QIAGEN N.V. common shares are being removed from listing and registration on the New York Stock Exchange in accordance with applicable SEC and Exchange rules.

Which QIAGEN N.V. securities are affected by this NYSE action?

The filing covers QIAGEN N.V. common shares, which are being struck from listing and registration on the New York Stock Exchange.

Is the QIAGEN N.V. NYSE delisting voluntary or forced?

The document states that QIAGEN has complied with Exchange rules and 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration.

Who is certifying the removal of QIAGEN N.V. shares from the NYSE?

The New York Stock Exchange LLC certifies it has reasonable grounds to believe it meets all requirements to file Form 25 and signs the notification through an authorized representative.

Which regulatory provisions are cited in QIAGEN N.V.’s delisting notice?

The filing references 17 CFR 240.12d2-2(a), 17 CFR 240.12d2-2(b), and 17 CFR 240.12d2-2(c), which govern removal from listing and voluntary withdrawal of securities.

Will QIAGEN N.V. (QGEN) still be registered under Section 12(b) after this action?

No. The Form 25 is a notification of removal from listing and/or registration under Section 12(b) for QIAGEN N.V.’s common shares on the NYSE.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/08/2026 - 09:50 AM EST Learn about SEC filing dates

UNITED STATES

OMB APPROVAL

OMB Number:			3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:			1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-38332

Issuer:	QIAGEN N.V.
Exchange:	NEW YORK STOCK EXCHANGE LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	HULSTERWEG 82
	Venlo		5912 PL
Telephone number:					+31-77-355-6600

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Common Shares

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, NEW YORK STOCK EXCHANGE LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2026-01-08	By	Tyler Mastronardi		Analyst, Market Watch
Date		Name		Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.